Trials / Completed
CompletedNCT02967679
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- MedDay Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Peripheral Neuropathy
- Charcot-Marie-Tooth Disease
- Charcot-Marie-Tooth Disease Type 1A
- Charcot-Marie-Tooth Disease, Type 1B
- Anti-MAG Neuropathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MD1003 |
Timeline
- Start date
- 2016-12-05
- Primary completion
- 2019-03-18
- Completion
- 2019-03-18
- First posted
- 2016-11-18
- Last updated
- 2020-11-02
- Results posted
- 2020-11-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02967679. Inclusion in this directory is not an endorsement.